Jenburkt Pharma (524731)

Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROE of 20.55% and ROCE of 27.18% indicate strong capital efficiency
• P/E of 13.67 is reasonable for a profitable pharma business
• Sales growth of 16.62% shows underlying demand
• Latest quarter net margin is roughly 14% (₹6 Cr profit on ₹43 Cr sales)
• Dividend yield of 1.79% provides some income while waiting

Concerns

• Profit growth is negative at -8.91% despite top-line growth
• Piotroski F-Score of 4/9 suggests deteriorating financial fundamentals
• Current price of ₹865.75 is below the stated 52-week range of ₹944–₹1321, indicating negative market sentiment
• Insufficient data on promoter holding and debt/equity, so balance-sheet risk is unclear

AI Analysis

Jenburkt Pharma is a small pharmaceutical business, and the numbers leave me respectfully cautious. At ₹865.75, the market cap is ₹387 Cr and the P/E is 13.67. That is a reasonable entry price if earnings are durable. The book value is ₹354.77, so I am paying 2.44 times equity for a company that earns 20.55% on equity and 27.18% on capital. Those returns suggest a decent business, although the data don't reveal patents, brands, or market share, so I cannot claim a wide moat. Debt/equity is listed as N/A, so I will not assume a clean balance sheet; knowing leverage is essential. Sales grew 16.62%, but profit fell 8.91%. The latest quarter shows ₹43 Cr of sales and ₹6 Cr of profit, a margin near 14%. The PEG ratio of 0.82 looks appealing only if that growth is profit, not just revenue. The stock trades at ₹865.75, below the stated 52-week range of ₹944–₹1321; Mr. Market is clearly skeptical. The Piotroski score of 4 out of 9 adds to my caution. This is not a fast grower. It may be a turnaround, but I need evidence. The 1.79% dividend offers some return while I wait. My discipline is simple: price is what you pay, value is what you get. At this price I pay a fair price for a business with mixed signals. I would wait for profit growth to turn positive and for disclosures to improve before calling this a wonderful investment.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer